CanSinoBIO is jointly developing the inhalation vaccine with the Beijing Institute of Biotechnology.
According to the CEO’s statement, who also spoke to CNBC on Sunday, the inhaled vaccine could be more effective than the injected version as the virus enters the body through the airways.
Theoretically, an inhaled vaccine could provide more protection by activating antibodies or T cells in the airways.
Efficacy rates for China’s Covid vaccines have been found to be lower than for those developed by Pfizer-BioNTech and Moderna, reported CNBC.
The CEO said the company has used the same concept to develop an inhalation vaccine for tuberculosis or TB.